

Drug Monograph

Drug/Drug **Aveed™ (testosterone undecanoate) vial/ androgen**

Class:

Prepared for: MO HealthNet

Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.	
Dosage Forms:	Aveed™ is available in a single use vial containing 250 mg/mL testosterone undecanoate.	
Manufacturer:	Endo Pharmaceuticals Solutions Inc. Malvern, PA 19355	
Indications:	Aveed™ injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone including primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).	
Costs:	\$275 per 3 mL vial of Aveed™ WholesaleAcquisitionCost	
Summary of Findings:	MO HealthNet Division recommends Open Access status for this product.	
Status Recommendation:	<input type="checkbox"/> Prior Authorization (PA) Required	<input type="checkbox"/> Clinical Edit
	<input type="checkbox"/> Fiscal Edit	<input checked="" type="checkbox"/> Open Access
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE	<input type="checkbox"/> Non-Preferred Agent
	<input type="checkbox"/> Appropriate Indications	<input checked="" type="checkbox"/> No PA Required

Prepared By: Katie Wilbers, PharmD

Date: May 16, 2014